艾力斯核心技术人员离职！

Core Insights - Shanghai Ailis Pharmaceutical Technology Co., Ltd. announced a strategic adjustment of its core technical personnel on November 28, 2025 [1] - The company has added Mr. Gao Changshou and Mr. You Fei as core technical personnel, while Mr. Luo Huibing and Mr. Xie Jingtian have left their positions due to personal reasons [2][5] - The departures of the two core technical personnel will not affect the company's intellectual property integrity or core competitiveness [7] Personnel Changes - Mr. Luo Huibing, who has over 20 years of new drug research experience, played a significant role in the development of key products, including the compound design and optimization of the core product, Fumetinin [4][6] - Mr. Xie Jingtian contributed to the formulation and production process development of key projects, including Fumetinin, during his tenure at the company [6] - Both departing personnel held shares in the company, with Mr. Luo holding 0.6454% and Mr. Xie holding 0.0561% [5][7] New Core Technical Personnel - The newly appointed core technical personnel, Mr. Gao Changshou and Mr. You Fei, have strong industry backgrounds and extensive research experience, both holding U.S. citizenship and doctoral degrees [8][9] - Mr. Gao Changshou is the current Chief Technology Officer and has a background in protein and antibody drug development, having previously worked at AstraZeneca and Innovent Biologics [9][10] - Mr. You Fei serves as the R&D Executive Director and has experience in innovative drug development from his time at AstraZeneca and Innovent Biologics [10] R&D Team Overview - Following the personnel adjustments, the company's core technical team now includes Gao Changshou, You Fei, Li Qing, Liang Chunqing, Jiang Yong, Zhang Qiang, and Zhou Huayong, covering key areas in small and large molecule drug development [10] - As of June 2025, the company's R&D team consists of 270 members, including 112 with master's degrees and 26 with doctoral degrees [11]